A-280 The Good, the Bad, and the Downright Inappropriate reporting of Gram Positive Resistance Genes in a Proficiency Testing Program

E Mills,D Casey,L Kolehmainen
DOI: https://doi.org/10.1093/clinchem/hvae106.277
IF: 12.114
2024-10-27
Clinical Chemistry
Abstract:BackgroundMolecular technologies can rapidly identify the pathogen, allowing for the correct antimicrobial agent to be used for initial treatment. Many laboratories have implemented molecular technologies to identify the causative agents of infections from various bodily sources. Screening for potential resistance genes to common antimicrobial agents provides high value to clinicians to help guide optimal antimicrobial therapy selection. CLIA '88 required proficiency testing for physician office laboratories in 1994. This was in addition to the requirement for hospital and reference laboratories instituted under CLIA '67. This study compares the accuracy of laboratory performance for molecular multiplex platforms in the detection of Gram positive resistance genes from gold standard qualified samples in a novel proficiency program.MethodsAmerican Proficiency Institute, an independent proficiency testing provider, reviewed the reporting of various molecular multiplex systems against simulated patient samples in proficiency samples offered in 2023. Participants were instructed to only report resistance genes their systems were capable of testing for, and ensure they were appropriate for the organism recovered. Failure rates for participants were evaluated against an 80% participant consensus standard for detection of resistance genes.ResultsDuring the 2023 proficiency year, Gram positive targets were included 14 times in 4 different multiplex programs. Accuracy for correct reporting of resistance genes appropriate for the organism recovered ranged between 71.0%- 100%. Conversely, the number of laboratories reporting resistance genes that were inappropriate for the organism recovered ranged between 2.0% - 67.0%.ConclusionsBased on the results reported by participants in API's proficiency event, Molecular Multiplex platforms are accurately identifying Gram positive resistance genes. However, many participants using both FDA approved and LDT systems reported results for resistance genes that were not applicable for the organism recovered. This inaccurate reporting could potentially lead to inappropriate antimicrobial therapies being prescribed.
medical laboratory technology
What problem does this paper attempt to address?